Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

V. Heymach, John; H. Harpole, David; Mitsudomi, Tetsuya; M. Taube, Janis; Gálffy, Gabriella; J. Hochmair, Maximilian; Winder, Thomas; А. Зуков, Р.; Garbaos, Gabriel; Gao, Shugeng; Kuroda, Hiroaki; Ostoros, Gyula; V. Tran, Tho; You, Jian; Lee, Kang‐Yun; Antonuzzo, Lorenzo; Pápai-Székely, Zsolt; Akamatsu, Hiroaki; Biswas, Bivas; I. Spira, Alexander; Crawford, Jeffrey; Le, Ha; Aperghis, Mike; J. Doherty, Gary; Mann, Helen; M. Fouad, Tamer; Reck, Martin

doi:10.1056/nejmoa2304875

Public

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Oct 23, 2023

Authors:

John V. Heymach

David H. Harpole

Tetsuya Mitsudomi

Abstract

Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to improve long-term outcomes. Download a PDF of the Research Summary. We randomly assigned patients with resectable NSCLC (s...

Subject

Durvalumab

Perioperative

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!